Elanco Animal Health Incorporated
Rank #366StartupELAN · NYSE · Healthcare
Elanco Animal Health Incorporated (ELAN) — Rank #366 by gross profitability (GP/assets 0.19) · ROE -3.5% · Piotroski F-Score 6 / 9.
As-of 2026-09-15 · CIK 0001739104 · all metrics point-in-time as of the filing date.
About
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
Show moreShow less
The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians.
Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- elanco.com
Price History
Company Snapshot
P/S is the primary valuation lens for pre-profit companies.
Market Cap
$11.57B
P/E (annual)
—
P/S (annual)
2.5
P/B
1.8
P/OCF (annual)
20.7
Shareholder Yield
0.2%
Employees
9,400
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NYSE
Signal Flags
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
2/2 passTerry Smith quality gate
Passes 1/5 Terry Smith thresholds4 of 5 thresholds not computable from filed data.
What Growth Is Priced In
Implied revenue growth (10Y)
17.3%
The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).
Buyback tailwind: -0.2% — per-share value needs a total required return of 17.1% once share-count change is priced in.
vs. own 6-year median revenue growth: 3.4%
priced above its own historyCost-of-equity sensitivity (implied growth at different discount rates)
r = 8%
12.4%
r = 10% (base)
17.3%
r = 12%
21.5%
Net debt / market cap: 33.6%— material leverage inflates the implied growth read.
Valuation History
Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.
P / S
Price / revenue per share
P / B
Price / book value per share
P / GP
Price / gross profit per share
P / FCF
Price / free cash flow per share
Disclosure regression check
A previously-disclosed line item is no longer reported. Worth checking the filing for why.
Burn rate (cash flow) is the primary read at this stage — TAM and product-market fit aren't metrics this dashboard tracks.
Profitability
Gross profitability (GP / assets)
0.19
Primary signal (Novy-Marx).
9th of 9 SIC 2834 peers
Return on equity
-3.5%
Gross margin
55.0%
9th of 9 SIC 2834 peers
Revenue growth (YoY)
6.2%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
2.2%
Revenue CAGR (5Y)
7.6%
Earnings CAGR (3Y)
—
FCF CAGR (3Y)
-3.4%
Anti-fragile safety
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
1.06
6th of 9 SIC 2834 peers (best = lowest)
Current ratio
2.05×
7th of 9 SIC 2834 peers
Quick ratio
0.87×
Net cash
-$3.87B
Cash & equivalents minus total debt.
Cash-flow health
Free cash flow
$284.00M
Operating cash flow minus capex.
Positive free cash flow
FCF / net income
2.22
Cash-backing of earnings.
FCF/NI divergence
Unfavorable divergence (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
1.4%
Stock-based comp intensity.
Piotroski F-Score
F-Score
6 / 9
Fundamental-strength score (0-9).